Insulin action and often glucose-stimulated insulin secretion are reduced in obesity. In addition, the excessive intake of lipids increases oxidative stress leading to overt type 2 diabetes mellitus (T2DM). Among the antioxidative defense systems, peroxiredoxin 6 (PRDX6) is able to reduce H₂O₂ and short chain and phospholipid hydroperoxides. Increasing evidences suggest that PRDX6 is involved in the pathogenesis of atherosclerosis and T2DM, but its role in the etiopathology of obesity and its complications is still not known. Therefore, in the present study, we sought to investigate this association by using PRDX6 knockout mice (PRDX6−/−). Metabolic parameters, like carbon dioxide (VCO₂) production, oxygen consumption (VO₂), and the respiratory exchange ratio (RER), were determined using metabolic cages. Intrapertitoneal insulin and glucose tolerance tests were performed to evaluate insulin sensitivity and glucose tolerance, respectively. Liver and pancreas histochemical analyses were also evaluated. The expression of enzymes involved in lipid and glucose metabolism was analyzed by real-time PCR. Following 24 weeks of high-fat-diet (HFD), PRDX6−/− mice showed weight gain and higher food and drink intake compared to controls. VO₂ consumption and VCO₂ production decreased in PRDX6−/− mice, while the RER was lower than 0.7 indicating a prevalent lipid metabolism. PRDX6−/− mice fed with HFD showed a further deterioration on insulin sensitivity and glucose-stimulated insulin secretion. Furthermore, in PRDX6−/− mice, insulin did not suppress adipose tissue lipolysis with consequent hepatic lipid overload and higher serum levels of ALT, cholesterol, and triglycerides. Interestingly, in PRDX6−/− mice, liver and adipose tissue were associated with proinflammatory gene upregulation. Finally, PRDX6−/− mice showed a higher rate of nonalcoholic steatohepatitis (NASH) compared to control. Our results suggest that PRDX6 may have a functional and protective role in the development of obesity-related metabolic disorders such as liver diseases and T2DM and may be considered a potential therapeutic target against these illnesses.
1. Introduction

Obesity is a chronic disease characterized by higher levels of insulin resistance that contribute to type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD) [1], cardiovascular complications, and premature death [2]. Higher fat depots, in fact, are associated with increased levels of insulin resistance, impaired glucose tolerance, T2DM, and dyslipidemia [3]. However, even if several hypotheses and theories have been postulated so far, the precise mechanisms underlying the pathophysiological link between obesity and insulin resistance and their correlated diseases have not been defined yet. Among them, enhanced liver storage of free fatty acids, increased oxidative stress levels, and activation of proinflammatory response have been demonstrated to play an important role in the interlink between obesity, insulin resistance, and their complications [4]. In overnutrition conditions such as obesity, an excess of lipids might accumulate in nonadipose tissue, which have a reduced capacity of triacylglycerol (TAG) storage. This phenomenon might increase oxidative stress as reported in the liver of obese patients with steatosis [5].

Recently, we demonstrated that peroxiredoxin 6 knock-out mice (PRDX6^−/−) developed a phenotype similar to an early stage of T2DM and were characterized by an impairment in muscle insulin sensitivity and glucose-stimulated insulin secretion [6]. Moreover, the same animals showed a hepatic proinflammatory state with typical nonalcoholic fatty liver disease (NASH) morphological features [6]. Our results innovatively suggested that PRDX6 could be involved in the complex interaction between the regulation of glucose homeostasis, lipid metabolism, and inflammatory response.

PRDX6 belongs to the peroxiredoxins (PRDXs), a family of antioxidant enzymes able to catalyze the reduction of hydrogen peroxide (H₂O₂), organic peroxides (ROOR′), and peroxynitrite (ONOO−) [7, 8]. Among those, PRDX6 is the only bifunctional enzyme which acts as glutathione peroxidase and phospholipase A2 (PLA2) and is able to hydrolyze phospholipids [9]. PRDX6 is widely expressed in all tissues, reaching higher levels of expression in the liver, pancreas, and kidneys [10]. Interestingly, PRDX6 concentrations are higher in hepatocytes, serving as oxidant scavengers against liver reactive oxygen species (ROS) [10].

Supporting the hypothesis that PRDX6 may be pivotal in the physiological link between glycemic and lipid components of metabolism, another study, using PRDX6 mice fed with a high-fat diet (HFD), demonstrated that these rodents were more susceptible in developing atherosclerosis compared to controls [11]. PRDX6^−/− mice exposed to an atherogenic diet showed higher levels of plasma lipid peroxides and a consequent increase in the macrophage oxidation of low-density lipoproteins (LDL) [11], since LDL oxidation is peroxide-dependent [12]. However, despite these evidences, so far, the role of PRDX6 in the modulation of adipose tissue functionality, dyslipidemia, and progression of fatty liver diseases has not been investigated. In the present study, we analyzed the impact of PRDX6 in these processes by using a model of PRDX6^−/− mice in response to HFD for 24 weeks.

2. Materials and Methods

2.1. Experimental Animals. Animals were maintained in a temperature-controlled room on a 12 h:12 h light-dark cycle with access to food and water ad libitum unless otherwise noted. Mice were fed either with standard chow diet (SCD) (Mucedola Srl, Settimo Milanese, Italy, code 4RF18) with 10% calories from fat or with HFD (58% fat, 25.5% carbohydrate, and 16.4% protein—Research Diets, Inc., NJ, USA, code D12331). Male and female PRDX6^−/− mice were gently provided by Professor Xiaosong Wang [10]. C57BL/6j mice were purchased from the Jackson Laboratory (Bar Harbor, Maine, USA). Genotyping of the animals was performed using DNA extracted from a small piece of tail (3-5 mm). The following primers were used: 0366 5′-CTT TGA ACA GAA CCA GGC AGG-3′, 0368 5′-CAG GAT GGA GCC TCT ATG CC-3′, and 0369 5′-TGG CTT CTG AGA CCG AAA GAA-3′. The study was approved by the University of Rome “Tor Vergata” Animal Care and Use Committee.

2.2. Glucose and Insulin Tolerance Test. Mice were fasted for 16 hours (h) and an Intraperitoneal Glucose Tolerance Test (IPGTT) was administered by intraperitoneal injection of 2 g/kg glucose. Blood samples were taken from the retroorbital capillary plexus at the Times (T) of 0, 15, 30, 60, 90, and 120 min, and glycaemia was measured using an automated OneTouch LifeScan Glucometer (Milpitas, CA) [6]. Insulin Tolerance Test (ITT) was performed after injecting 0.75 IU/kg insulin in mice for 4h. Glucose levels were measured at T 0, 15, 30, and 60 min [6].

2.3. Insulin Measurements. Blood insulin concentrations were measured in basal conditions and after IPGTT using a Mouse Insulin ELISA Kit (Mercodia, Uppsala, Sweden) according to the manufacturer’s protocol. Briefly, plasma samples were loaded on a 96-well plate coated with anti-insulin antibodies and allowed to react with insulin antibodies conjugated with peroxidase for 2h. A simple washing step removed unbound antibodies. The bound conjugates were detected by reaction with 3,3′,5,5′-tetramethylbenzidine. Then, the reaction was stopped by adding 0.5 M H₂SO₄ and was read spectrophotometrically at 450 nm.

2.4. RNA Extraction and Real-Time PCR. Total cellular RNA isolation from the liver, skeletal muscle, and white adipose tissue was obtained using the TRIzol Reagent (Invitrogen Corp., Carlsbad, CA). The High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA) was used to reverse-transcribed 2 μg of total RNA into cDNA. Quantitative real-time polymerase chain reaction (RT-PCR) was performed using an ABI PRISM 7500 System and TaqMan reagents (Applied Biosystems). mRNA expression was monitored using commercial primers that were purchased from Life Technologies: sterol regulatory element binding transcription factor 1 (SREBP1-c)—Mm00550338_m1; TNF receptor superfamily member 6 (FAS)—Mm01204974_m1; CD36—Mm01135198_m1; patatin-like phospholipase domain containing 2 (PNPLA2)—Mm00503040_m1; acyl-coenzyme A oxidase 1, palmitoyl (Acox-1)—Mm01246834_
m; carnitine palmitoyl transferase 1a (Cpt1-α)—Mm01231183_m1; phosphoenolpyruvate carboxykinase 1 (Pepck)—Mm01247058_m1; glucose 6 phosphate, catalytic subunit 3 (G6P)—Mm00616234_m1; CD68—Mm03047340_m1; EGFlike module containing, mucin-like, hormone receptor-like sequence 1 (F4/80)—Mm00802529_m1; integrin alpha X (Cd11c)—Mm00498698_m; CD19—Mm00515420_m1; CD3—Mm00442746_m1; chemokine (C-C motif) ligand 3 (MCP-1)—Mm00441259_g1; chemokine (C-X-C motif) ligand 1 (KC)—Mm00207460_m; interleukin 1 beta (IL-1β)—Mm00434228_m; interleukin 10 (IL-10)—Mm00439614_m; tumor necrosis factor alpha (TNF-α)—Mm00443258_m1; interleukin 6 (IL-6)—Mm00446190_m1; interleukin 21 (IL-21)—Mm00517640_m1; adiponectin—Mm00456425_m1; leptin—mM00434759-m1; chitinase-like 3 (Ym1)—Mm00657889_mH; C-type lectin domain family 10, member A (Mgl1)—Mm00546124_m1; macrophage galactose N-acetylgalactosamine-specific lectin 2 (Mgl2)—Mm00460844_m1; and arginase, liver (Argl)—Mm00475988_m1. Gene expression was calculated using the comparative ΔΔCT method, and the values were expressed as 2−ΔΔCT (Livak KJ, Schmittgen TD). Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method [13]. All results were normalized using β-actin.

2.5. Histological Evaluation of Nonalcoholic Steatohepatitis and Pancreatic Islets. To obtain the percentage of islets and number of pancreatic islets, a digital camera (Dxm1200F, Nikon Italia SpA, Milan, Italy) and the Scion Image software (Scion Corporation, Frederick, MD, USA) at a 20x magnification were used. Mice liver were fixed in 10% formalin overnight, embedded in paraﬁlm, cut at 4 μm thickness, and stained with haematoxylin and eosin. Steatosis score was evaluated as previously described [14]. The number of pancreatic islets and percentage of islet area were calculated for each pancreas on at least 5 serial sections at intervals of 200 μm. All analyses were performed in a blinded fashion by two different pathologists, with an interobserver variability less than 5%.

2.6. Metabolic Studies. Metabolic studies were performed using the LabMaster system (TSE Systems, Bad Homburg, Germany) [15]. All mice used were acclimatized in metabolic cages for 48 h before measurements of each parameters with ad libitum access to food and drink. VCO2 and VO2 were determined using O2 and CO2 sensors calibrated against a standard gas mix containing defined quantities of O2 and CO2. The ratio between VCO2 and VO2 indicates the respiratory exchange ratio (RER) [15]. Animal activity was expressed as all of the movement recorded across the X and Y axes [16]. Daily food and drink intake were monitored by weighing food hoppers and drink bottles. All the measurements were taken every 15 min for a total of 24 h.

2.7. Total Ketone Body Measurement. Total serum ketone body (TKB) level was obtained using a ketone body assay (Sigma-Aldrich, St. Louis, MO, USA). Briefly, 5 μl of blood sample and standard solution were added to each of the wells. The levels of acetoacetic acid (AcAc) and 3-hydroxybutyric acid (BOH) were determined using the reaction catalyzed by 3-hydroxybutyrate dehydrogenase (HBDH) in which the change in absorbance, measured at 340 nm, is directly related to AcAc and BOH concentration [17]. TKB concentration was calculated using the following formula: TKB = (AcAc) + (BOH).

2.8. Free Fatty Acid Quantification. Total serum free fatty acid (FFA) level was obtained using the FFA Quantification Assay Kit (Abcam). According to the manufacturer’s protocol, FFA were converted to their CoA derivatives and oxidized with the generation of color that was read at λ = 570 nm.

2.9. Blood Biochemistry. Serum cholesterol, triglyceride, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and HDL cholesterol levels were measured by the Keylab System (BPC Biosed S.r.l., Rome Italy) [18]. Very low-density lipoproteins (VLDL) were calculated using the following formula: triglycerides/5 [19].

2.10. Statistical Analysis. All data are expressed as mean ± standard error of the mean (SEM). Statistical analysis was performed using unpaired one-tailed Student’s t test or two-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc test. Results were analyzed using GraphPad Prism 5 (La Jolla, CA, USA), and a p < 0.05 was considered statistically significant.

3. Results

3.1. Basal Metabolism Decreases in Mice Lacking PRDX6 after HFD. First, since PRDX6 has an important role in regulating glucose homeostasis [6], we tested whether differences in basal metabolism were present between PRDX6−/− and WT (wild type) mice. To reach our objective, metabolic cages were utilized. PRDX6−/− mice fed with SCD, however, presented a statistically significant decrease in VO2 consumption (p < 0.0005) and an increase in RER (Figure 1(b)). Gain of weight of PRDX6−/− mice compared to WT mice (Figure 1(b)). Increase in weight compared to WT mice (Figure 1(b)) that was already evident after one month of diet (<0.004) (Figure 1(b)). Gain of weight of PRDX6−/− mice compared to WT mice was related to more food (p < 0.0005) (Figure 1(d)) and drink intake (p < 0.0005) (Figure 1(f)). Horizontal and vertical movements in PRDX6−/− mice fed with HFD were signiﬁcantly reduced as compared to WT (p < 0.0005) fed with the same diet (Figure 1(h)), suggesting an impairment in physical activity in HFD-feeding PRDX6−/− mice.

After 24 hours in metabolic cages, no diﬀerences in VO2, VCO2, and RER were observed between PRDX6−/− with the same diet (Figure 1(i)). However, after HFD, indirect calorimetric measurement reported that PRDX6−/− mice had a signiﬁcant decrease in VO2 consumption (p < 0.0001) and VCO2 (p < 0.0001) production and an increase in RER.
Figure 1: Continued.
(p < 0.05) compared to WT mice. Both mouse strains had a decrease in RER when fed with HFD compared to SCD, but PRDX6−/− mice had relatively less fat oxidation compared to WT mice, since RER values were significantly higher (p < 0.05) (Figure 1(j)), confirming the hypothesis of a lower basal metabolism in these animals after an intake of a high amount of fat. However, RER values lower than 0.7 suggested the synthesis of carbohydrates or ketone body metabolism in mice lacking of PRDX6 [20].

3.2. Function and Anatomical Structure of Pancreatic Beta Cells Are Impaired in PRDX6−/− Mice Fed with HFD. Mouse lacking PRDX6 but fed with SCD develop a mild form of DM, mainly linked to higher levels of insulin resistance associated with a defect of glucose-stimulated insulin secretion (GSIS) [6]. In order to further understand the impact of this antioxidant enzyme on the regulation of glycemic homeostasis and maintenance of a functional pancreatic β-cell mass, we further investigated the metabolic response of PRDX6−/− mice with higher fasting glucose levels are insulin resistant. Measurement of insulin secretion during IPGTT were significantly reduced at 15 (p < 0.001), 60, and 120 min (p < 0.01) in PRDX6−/− mice compared to WT mice (Figure 2(c)). The insulinogenic index was also calculated to investigate the function of pancreatic β-cells at 15 min, resulting in lower levels in PRDX6−/− mice (p < 0.005) (Figure 2(d)), further confirming the impairment of β-cell function in the absence of PRDX6, as previously reported [6].

Similarly, histochemical analysis of pancreas established previous findings [6], showing that PRDX6−/− mice have a significantly lower number (p < 0.05) and size (p < 0.05) of pancreatic islets compared to WT mice (Figures 2(e), 2(f), 2(g), and 2(h)). These results suggest that the absence of this specific antioxidant enzyme may influence both the function and the anatomical structure of pancreatic islets in mice fed with a normal diet but with a further increase in HFD.

3.3. Lack of PRDX6 Impaired Lipid and Glucose Metabolism. Lipid metabolism impairment and FFA trafficking from adipose tissue to liver are key events in the development of T2DM and NAFLD [21]. Therefore, we analyzed the mRNA expression of genes involved in adipose tissue lipid biogenesis and transport (SREBP1-c, FAS, and CD36) (Figure 3(a)), lipolysis (PNPLA2) (Figure 3(b)), and β-oxidation (Acox-1 and Cpt1-a) (Figure 3(b)). PRDX6−/− mice displayed significantly increased levels of PNPLA2 compared to WT mice (p < 0.05) (Figure 3(b)). PNPLA2 is the principal enzyme
Figure 2: Continued.
Increased Risk of Developing NASH in PRDX6 Knockout Mice after a Proinflammatory Diet. NAFLD is the most common liver disease in obese and T2DM patients, and its main feature is the accumulation of triglycerides in hepatocytes with consequent steatosis [27]. Often, this condition evolves to NASH [28]. Based on the data reported above, we aimed to determine the role of PRDX6 on NAFLD and its progression to NASH. We evaluated serum levels of ALT, AST, cholesterol, VLDL, and triglycerides, and the liver histological analysis in PRDX6⁻/⁻ and WT mice fed with HFD. Circulating serum levels of cholesterol and VLDL in PRDX6⁻/⁻ mice were raised compared to WT mice (p < 0.005 and p < 0.05, respectively) (Figure 4(a)). Indeed, HDL cholesterol blood concentrations were similar between the two groups of animals (Figure 4(a)). Furthermore, the levels of triglycerides increased in PRDX6⁻/⁻ in comparison to WT mice (p < 0.05). As an important marker of hepatic injury, ALT level was higher (p < 0.05) in PRDX6⁻/⁻ mice compared to WT mice (Figure 4(a)). No significant change was evident in the AST level between the two groups of animals (Figure 4(a)).

Histological analysis of the liver in mice fed a HFD and obese mice showed a histological pattern characterized by microvesicular steatosis in WT mice, as expected, while a microvesicular and macrovesicular state of steatosis prevailed in PRDX6⁻/⁻ mice, with signs of lobular inflammation and hepatocellular ballooning (Figure 4(b)). Indeed, the steatosis score in PRDX6⁻/⁻ mice was significantly higher compared to WT mice (Figure 4(c)) (p < 0.005).

To further investigate whether the higher level of steatosis present on PRDX6⁻/⁻ mice depended on the increased lipid metabolism or by the increased hepatic uptake of FFA, genetic expression (mRNA) of the main enzymes involved in these pathways were evaluated (SREBP1-c, FAS, and CD36). Interestingly, the expression of CD36, which mediates the hepatic uptake of FFA [29], increased in PRDX6⁻/⁻ mice (p < 0.05) (Figure 4(d)). In addition, the mRNA levels of enzymes involved in lipolysis and β-oxidation (PNPLA2, Acox-1, and Cpt1-a) were examined. Genetic expression of PNPLA2 in the liver of PRDX6⁻/⁻ mice did not differ compared to WT mice (Figure 4(e)), suggesting a tissue-specific pattern of expression of this gene. Similar data were catalyzing the initial step of triglyceride hydrolysis in adipocytes [22, 23]. Indeed, the serum levels of FFA were significantly higher in PRDX6⁻/⁻ than WT mice (p < 0.05) (Figure 3(c)). Thus, the higher expression of PNPLA2 in PRDX6⁻/⁻ mice may enhance the hydrolysis of triglycerides, increasing FFA blood levels, the risk of its accumulation in the liver, and the development of NAFLD. In obese patients with T2DM, higher levels of circulating FFA and/or increased rate of lipolysis lead to gluconeogenesis [24]. Moreover, a massive mobilization of FFA from adipose tissue results in an increased production of ketone bodies derived from FFA oxidation into AcAc and BOH in the liver, and in smaller proportion, in muscle [25]. Therefore, a link between FFA, liver metabolism, gluconeogenesis, and ketogenesis is well established.

In our model, a lack of PRDX6 in an animal fed with HFD was associated with a significant upregulation of gluconeogenesis in comparison with WT mice (Figure 3(d)). Indeed, mRNA expression of Pepck (p < 0.05) and G6P (p < 0.05), the two key enzymes which regulate the first and the latest reaction of gluconeogenesis [26], was higher in PRDX6⁻/⁻ than in WT mice.

To determine the total serum ketone bodies, the amount of AcAc and BOH was calculated. PRDX6⁻/⁻ mice fed with HFD showed an increased production of blood total ketone bodies compared to WT mice (p < 0.05) (Figure 3(e)), suggesting that high levels of FFA released from adipose tissue may have a significant effect on ketogenesis in these animals. This is in agreement with the RER levels < 0.7, which suggested an increased ketone body metabolism.

3.4. Increased Risk of Developing NASH in PRDX6 Knockout Mice after a Proinflammatory Diet. NAFLD is the most common liver disease in obese and T2DM patients, and its main feature is the accumulation of triglycerides in hepatocytes with consequent steatosis [27]. Often, this condition evolves
Figure 3: PRDX6−/− mice show an upregulation in the release of free fatty acid from adipose tissue, liver gluconeogenesis, and ketogenesis. mRNA expression of genes involved in (a) lipid biogenesis (SREBP1-c, FAS, and CD36), (b) lipolysis and β-oxidation (PNPLA2, Acox-1, and Cpt1-α), (c) total serum FFA concentration, (d) liver gluconeogenesis (Pepck, G6P), and (e) total serum ketone body concentration that was calculated using the following formula: TKB = (AcAc) + (BOH) (n = 8 mice per group). a.u.: arbitrary units. The results are expressed as means ± SEM. Statistically significant differences between PRDX6−/− mice and WT mice are indicated; *p < 0.05.
Figure 4: PRDX6 deficiency induces hepatic steatosis on HFD. (a) Measurement of cholesterol, triglycerides, VLDL, HDL, ALT, and AST. Following 24 weeks on HFD, fasting serum samples in WT (black bar) and PRDX6−/− mice (white bar) were taken (n = 5 mice per group). (b) Microscopic analysis of the liver section in WT and PRDX6−/− mice upon HFD for 24 weeks. The images are shown at 20x magnification. (c) Steatosis score valuation in WT (black bar) and PRDX6−/− mice (white bar) (n = 5 mice per group). mRNA expression of genes involved in (d) lipid biogenesis (SREBP1-c, FAS, and CD36) and (e) lipolysis and β-oxidation (PNPLA2, Acox-1, and Cpt1-α). The results are expressed as means ± SEM. Statistically significant differences between PRDX6−/− mice and WT mice are indicated; *p < 0.05 and **p < 0.005.
present for Cpt1-α, the protein responsible for the transport of fatty acyl-CoA through the inner mitochondrial membrane [30], and Accox-1, the enzyme that catalyzes the first step in peroxisomal β-oxidation [31] (Figure 4(e)). Based on these results, we may suggest that the steatosis state in the absence of PRDX6 and on HFD could be a consequence of hepatic lipid overload.

3.5. Effect of PRDX6 on the Inflammatory State. HFD is a pro-inflammatory input which mimics the obesity inflammatory pathological background [32]. By measuring the mRNA expression of cytokines and chemokines, as principal markers of inflammation in the pivotal tissues (adipose tissue, liver, skeletal muscle), we sought to understand the role of PRDX6 in this process. The list of markers measured by real-time PCR is reported in Table 1. After 24 weeks on HFD, PRDX6-/- mice showed a significant upregulation (p < 0.05) in the expression of genes coding for TNF-α, IL-1β, IL-6, and MCP-1 compared to WT mice, measured in the adipose tissue and in the liver (Table 1). In adipose tissue, a lack of PRDX6 also had a significant impact in leptin synthesis (p < 0.005), whereas the adiponectin level did not change (Table 1).

In the skeletal muscle, the PRDX6-/- mice only showed a higher expression for TNF-α and MCP-1 compared to WT, whereas the other cytokines did not change (Table 1), suggesting a specific effect of these enzymes in the regulation of the inflammatory process, which deserves further investigation.

4. Discussion

In the present study, innovatively, we reported a pivotal role of PRDX6 in the pathogenesis of obesity and related liver diseases, particularly nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. By using a model of PRDX6 knockout mice fed a HFD for 24 weeks, we demonstrated that a lack of this enzyme was associated with a significant weight gain due to increased food intake, and decreased physical activity. Drink intake was also enhanced in these mice, probably due to markedly elevated glucose levels, glycosuria, and osmotic diuresis. An increase in adipose tissue leptin production was observed, possibly linked to higher levels of hypothalamic leptin resistance [33], or to higher signals of energy repletion, since for unknown reasons, PRDX6-/- mice could be more exposed to an increase of palatable food in response to HFD. A proteomic study conducted in adipose tissue of mice fed a HFD for 24 weeks, we demonstrated that a lack of PRDX6 was associated with a higher glucose and ketone blood concentrations. Moreover, it might be also linked to higher weight gain in this strain due to a lesser capacity to oxidize fat compared to WT mice [35]. Furthermore, glucose-induced insulin release was reduced in PRDX6-/- mice along with a lower insulinogenic index. Lower insulin levels may be correlated with the observed increase in food intake in these mice, since insulin action in hypothalamic nuclei, like the arcuate nucleus [36] (central regulatory of feeding and energy homeostasis) when decreased, affects appetite and consequently body weight [37]. Finally, in the absence of PRDX6, pancreatic islets were reduced in number and size compared to WT highlighting a relevant role of PRDX6 in maintaining the structure of pancreatic β-cells [38]. Since PRDX6 is among the most important antioxidant enzymes in pancreatic β-cells, its absence can influence the cellular redox system and the insulin secretion as well. This has been hypothesized as the main mechanism underlying pancreatic dysfunction linked with a lack of PRDX6 since this enzyme may play a role at different cellular levels in controlling ROS production and therefore cellular functions, such as insulin secretion. In fact, a direct action of PRDX6 on mitochondria clearance [39] and in the modulation of electron transport chain [40] has been proposed, processes that are directly implicated with oxidative stress and oxidative stress-related diseases.

Several evidences outline a role of PRDX6 in the modulation of hepatic functions: PRDX1 expression was decreased in the liver of HFD-fed mice [41], PRDX4 transgenic mice were resistant to hepatic steatosis, and insulin resistance increased in response to HFD [42]. We found that PRDX6-/- mice have higher levels of insulin resistance [6], and PRDX6 protein and mRNA expression decreased in the liver of a mouse model of ethanol consumption [43]. In this study, we reported that HFD-fed PRDX6-/- mice showed advanced liver dysfunction with signs of lobular inflammation and hepatocellular ballooning indicating a condition of NASH, not present in WT mice. Liver metabolism was also affected by a significant upregulation in gluconeogenic and CD36 gene expression, which contribute to hepatic lipid accumulation in the presence of increased FFA supply, as documented by higher VLDL and FFA blood levels observed in PRDX6-/- mice. CD36, a scavenger receptor enhanced in the liver of HFD-induced obese mice [44], plays an important role in liver dysfunction progression [45]. Hepatic resident macrophages expressing CD36 contribute to the accumulation of a liver fat depot [46]. Additionally, CD36 recognizes specific fatty acids such as palmitate and oleic acids, activating intracellular signaling pathways which lead to proinflammatory cytokine production [47]. According to these findings, we reported that a lack of PRDX6 was associated with a higher level of inflammatory parameters in all tissues investigated, and in particular, the liver showed high levels of dendritic, T cell, and macrophage marker expression and increased levels of cytokines, such as IL-1β, TNF-α, and IL-6. Among those, TNF-α, specifically, has been shown to be directly involved in the development of hepatic steatosis and insulin resistance [48]. These results suggested that mice lacking PRDX6 were more prone to develop a severe form of liver dysfunction, such as NASH, highlighting the role of this antioxidant enzyme in the pathogenesis of metabolic liver disease in obese and diabetic conditions. The anti-inflammatory properties of PRDX6 were already reported in corneal cells, where the administration of this enzyme was able to reduce
increased pathway and the overproduction of ROS which leads to steatohepatitis (1 hit) follows the induction of an inflammatory state in liver and white adipose tissue. Gene expression analysis obtained by real-time PCR in WT mice and PRDX6−/− mice for leukocyte cell surface markers (CD68, F4/80, CD11c, CD19, CD3, Arg1, Mgl1, Mgl2, and YM1), chemokines (MCP-1 and Kc), and cytokines (IL-1β, IL-10, TNF-α, IL-6, and IL-21) (n = 8 mice per group). All the results were normalized using β-actin and expressed as means ± SEM. a.u.: arbitrary units; ND: not detectable; NS: not significant p value. *p < 0.05 and **p < 0.005.

| Gene (a.u.) | Adipose tissue | | | | Liver | | | | Skeletal muscle | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | WT mice | KO mice | p value | WT mice | KO mice | p value | WT mice | KO mice | p value | WT mice | KO mice | p value |
| IL-1β | 0.89 ± 0.57 | 1.84 ± 1.07 | <0.05 | 2.24 ± 1.74 | 8.68 ± 5.47 | <0.05 | 1.9 ± 2.29 | 1.91 ± 1.13 | NS |
| IL-10 | 1.76 ± 1.59 | 1.55 ± 1.1 | NS | 0.7 ± 0.45 | 4.10 ± 4.42 | <0.05 | 0.57 ± 0.28 | 1.18 ± 0.95 | NS |
| TNF-α | 1.03 ± 0.44 | 2.10 ± 1.35 | <0.05 | 0.59 ± 0.39 | 1.82 ± 1.34 | <0.05 | 0.88 ± 0.25 | 2.16 ± 0.06 | <0.05 |
| IL-6 | 0.86 ± 0.43 | 1.4 ± 0.64 | <0.05 | 1.36 ± 0.78 | 4.31 ± 2.69 | <0.05 | 1.52 ± 1.93 | 1.29 ± 1.17 | NS |
| IL-21 | 0.88 ± 0.54 | 0.96 ± 0.58 | NS | 2.77 ± 1.7 | 3.39 ± 1.34 | NS | ND | ND | ND |
| Leptin | 1.2 ± 0.58 | 4.7 ± 2.19 | <0.05 | ND | ND | ND | ND | ND | ND |
| Adiponectin | 0.46 ± 0.30 | 0.61 ± 0.2 | NS | ND | ND | ND | MD | ND | ND |
| MCP-1 | 1.35 ± 1.57 | 4.88 ± 2.18 | <0.05 | 0.62 ± 0.08 | 1.39 ± 0.37 | <0.05 | 1.51 ± 0.34 | 3.77 ± 1.64 | <0.05 |
| Kc | 1.5 ± 1.78 | 3.54 ± 3.99 | NS | 0.39 ± 0.17 | 7.4 ± 2.03 | <0.05 | 0.61 ± 0.33 | 0.84 ± 0.36 | ND |
| CD68 | 0.6 ± 0.42 | 1.29 ± 0.6 | <0.05 | 1.32 ± 0.27 | 1.66 ± 0.2 | NS | 0.94 ± 0.13 | 1.46 ± 1.71 | NS |
| F4/80 | 0.74 ± 0.32 | 1.45 ± 0.82 | <0.05 | 0.84 ± 0.21 | 2.37 ± 0.34 | <0.05 | 0.67 ± 0.21 | 0.62 ± 0.06 | NS |
| CD11c | 0.94 ± 0.55 | 5.87 ± 2.76 | <0.05 | 0.37 ± 0.16 | 1.41 ± 0.31 | <0.05 | 1.35 ± 0.7 | 2.50 ± 3.10 | NS |
| CD19 | 0.51 ± 0.33 | 0.94 ± 0.19 | <0.05 | 0.38 ± 0.37 | 0.32 ± 0.19 | NS | 1.88 ± 2.61 | 0.73 ± 0.42 | NS |
| CD3 | 0.4 ± 0.35 | 0.6 ± 0.58 | NS | 0.89 ± 0.6 | 2.26 ± 1.01 | <0.05 | 0.94 ± 0.41 | 1.01 ± 0.46 | NS |
| Arg1 | 0.96 ± 0.49 | 1.65 ± 0.81 | NS | 0.77 ± 0.38 | 0.94 ± 0.47 | NS | 0.65 ± 0.42 | 0.73 ± 0.37 | NS |
| Mgl1 | 1.57 ± 0.77 | 2.03 ± 0.99 | NS | 0.85 ± 0.39 | 1.72 ± 1.06 | NS | 1.37 ± 0.33 | 2.3 ± 0.99 | NS |
| Mgl2 | 0.87 ± 0.29 | 0.76 ± 0.19 | NS | 0.99 ± 0.25 | 2.15 ± 2.05 | NS | 1.32 ± 0.41 | 1.78 ± 0.41 | NS |
| YM1 | 1.65 ± 1.26 | 2.36 ± 0.5 | NS | 0.6 ± 0.41 | 2.53 ± 2.44 | NS | 0.27 ± 0.48 | 0.14 ± 0.13 | NS |

inflammation and apoptosis [49]. A recent study revealed that TNF-α or INF-γ decreased both the mRNA and protein expression of PRDX6 in pancreatic β cells, further confirming the crosslink between this antioxidant enzyme and tissue-specific inflammatory processes [50].

Obesity, a condition with chronic low-grade inflammation, is strictly linked with liver abnormalities such as NAFLD. According to the traditional “two-hit hypothesis,” NAFLD can evolve to NASH, when after triglyceride accumulation (1 hit) follows the induction of an inflammatory pathway and the overproduction of ROS which leads to steatohepatitis (2 hits) [51]. However, evidences now indicate that in conditions like obesity and insulin resistance, the increased flux of FFA from adipose tissue is the main cause of liver injury, through oxidative stress and inflammation, that progress to NASH [52]. In insulin resistance conditions, the antilipolytic effect of insulin on adipose tissue is decreased [53]. In association, the high PNPLA2 gene expression levels found in adipose tissue of PRDX6−/− mice may partially explain the increased levels of TG and liver lipid accumulation. Moreover, FFA released from adipose tissue cross the hepatic plasma membrane directly for diffusion or through the CD36 protein, the levels of which have been found enhanced in the liver of PRDX6−/− mice and in patients with NAFLD, and its expression is correlated with the hepatic lipid content [54]. Therefore, the increase in hepatic lipid content observed in these animals is mainly due to an increase in the incoming of lipids in the liver. Cholesterol and VLDL blood concentrations were increased in PRDX6−/− mice, together with higher levels of ALT. This is in agreement with the presence of NASH and the increase in liver lipid content of PRDX6−/− mice that lead to the alteration of liver metabolism and enhancement of VLDL production and secretion. A previous study [40] has already demonstrated a protective role for PRDX6 during hepatocellular injury, likely due to its strong expression in the liver, and downregulation of PRDX6 was reported in the liver of donors after brain death associated with oxidative stress induced by ischemia and hypoxia [55]. Recently, in agreement with our finding, it has been demonstrated in the PRDX6 transgenic mouse model that PRDX6 protects against NAFLD progression, preserving mitochondrial integrity in response to HFD [56]. Taken together, all these findings suggest that increasing the activity of this antioxidant enzyme may be a novel strategy to alleviate liver damage in dysmetabolic conditions, such as obesity and T2DM.

The strengths of the present study are as follows: the use of a novel genetic model of PRDX6−/− mice, a significantly long time of follow-up for an in vivo study (24 weeks), the use of proinflammatory HFD, and detailed measurement of histological and biochemical parameters. The main limitation to acknowledge for this study is that as in all genetic models of knockout animals, other unexpected compensatory or redundant antioxidant and anti-inflammatory mechanisms
may be present and it is very difficult to evaluate their effects [57].

5. Conclusion

In conclusion, in the present study, we reported a direct role of PRDX6 in the pathological link between obesity and liver diseases by the modulation of noxious oxidative stress and inflammation processes. A better understanding of the mechanisms underlying this link may allow us to develop novel therapeutic strategies against metabolic illnesses and their complications, which may have a direct effect in terms of extending longevity and preventing obesity comorbidity. Further studies to clarify the role of PRDX6 and metabolic diseases, such as obesity and liver dysfunction, are imperative.

Data Availability

All the data in the figures and tables used to support the findings of this study are included within the article.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Acknowledgments

This work has been supported by grants from the following foundations: PRIN 2017, #201793XZ5A_004, “Metabolic therapy of immuno-inflammation: in search for the best strategy to counteract type 2 diabetes and its complications”; Fondazione Umberto Di Mario; COREA Research Project, Italian Space Agency, ASI N 2013-084-R0; Evelyn F. McKnight Brain Research Foundation, Department of Neurology, University of Miami, Miami, FL, USA; PRIN 2015 #2015373Z39_009 “Pancreatic β-cell identity, glucose sensing, and the control of insulin secretion”; and Fondazione Roma—”Diabetes mellitus, regenerative and reparative processes, and improvement of pancreatic beta cell function: role of bone marrow-mesenchymal stem cells, microRNAs, M2 macrophages, and myeloid-derived suppressor cells.”

Supplementary Materials

Experimental flow diagram. In this study, WT and PRDX6-/- mice were fed with HFD. After 24 weeks of HFD diet, we performed (i) measurement of glucose homeostasis by IPGTT and ITT; (ii) histochemical analysis of pancreas; (iii) evaluation of NAFLD by calculation of the steatosis score and FFA metabolism; and (iv) real-time PCR analysis of the main genes involved in lipid and glucose metabolism as well as those implicated in inflammation in the liver, skeletal muscle, and adipose tissue. (Supplementary Materials)

References

[1] J. M. Hazlehurst, C. Woods, T. Marjot, J. F. Cobbold, and J. W. Tomlinson, “Non-alcoholic fatty liver disease and diabetes,” Metabolism, vol. 65, no. 8, pp. 1096–1108, 2016.

[2] U. Jung and M.-S. Choi, “Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease,” International Journal of Molecular Sciences, vol. 15, no. 4, pp. 6184–6223, 2014.

[3] K. M. Utzschneider and S. E. Kahn, “Review: the role of insulin resistance in nonalcoholic fatty liver disease,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 12, pp. 4753–4761, 2006.

[4] A. M. Gusdon, K. Song, and S. Qu, “Nonalcoholic fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 637027, 20 pages, 2014.

[5] A. Aronis, Z. Madar, and O. Tirossi, “Mechanism underlying oxidative stress-mediated lipotoxicity: exposure of J774.2 macrophages to triacylglycerols facilitates mitochondrial reactive oxygen species production and cellular necrosis,” Free Radical Biology and Medicine, vol. 38, no. 9, pp. 1221–1230, 2005.

[6] F. Pacifi, R. Arriga, G. P. Sorice et al., “Peroxisoridixin 6, a novel player in the pathogenesis of diabetes,” Diabetes, vol. 63, no. 10, pp. 3210–3220, 2014.

[7] Z. A. Wood, E. Schröder, J. R. Harris, and L. B. Poole, “Structure, mechanism and regulation of peroxiredoxins,” Trends in Biochemical Sciences, vol. 28, no. 1, pp. 32–40, 2003.

[8] L. B. Poole, A. Hall, and K. J. Nelson, “Overview of peroxiredoxins in oxidant defense and redox regulation,” Current Protocols in Toxicology, vol. 49, no. 1, pp. 7.9.1–7.9.15, 2011.

[9] A. B. Fisher, “Peroxisoridixin 6: a bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities,” Antioxidants & Redox Signaling, vol. 15, no. 3, pp. 831–844, 2011.

[10] X. Wang, S. A. Phelan, K. Forsman-Semb et al., “Mice with targeted mutation of peroxisoridixin 6 develop normally but are susceptible to oxidative stress,” The Journal of Biological Chemistry, vol. 278, no. 27, pp. 25179–25190, 2003.

[11] X. Wang, S. A. Phelan, C. Petros et al., “Peroxisoridixin 6 deficiency and atherosclerosis susceptibility in mice: significance of genetic background for assessing atherosclerosis,” Atherosclerosis, vol. 177, no. 1, pp. 61–70, 2004.

[12] J. P. Thomas, B. Kalyanaraman, and A. W. Girotti, “Involvement of preexisting lipid hydroperoxides in Cu²⁺-stimulated oxidation of low-density lipoprotein,” Archives of Biochemistry and Biophysics, vol. 315, no. 2, pp. 244–254, 1994.

[13] K. J. Livak and T. D. Schmittgen, “Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2ΔΔCT Method,” Methods, vol. 25, no. 4, pp. 402–408, 2001.

[14] D. E. Kleiner, E. M. Brunt, M. Van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005.

[15] H. X. Bian, Z. Y. Wu, B. Bao, and O. Tirossi, “1H NMR-based metabolic study reveals the improvements of bitter melon (Momordica charantia) on energy metabolism in diet-induced obese mouse,” Pharmaceutical Biology, vol. 54, no. 12, pp. 3103–3112, 2016.

[16] M. E. Edelsbrunner, E. Painsipp, H. Herzog, and P. Holzer, “Evidence from knockout mice for distinct implications of neuropeptide-Y Y2 and Y4 receptors in the circadian control of locomotion, exploration, water and food intake,” Neuropeptides, vol. 43, no. 6, pp. 491–497, 2009.
[17] T. Tong, S. E. Ryu, Y. Min et al., "Olfactory receptor 10j5 responding to α-cedrene regulates hepatic steatosis via the cAMP-PKA pathway," *Scientific Reports*, vol. 7, no. 1, article 9471, 2017.

[18] L. Campagnolo, M. Massimiani, G. Palmieri et al., "Biodistribution and toxicity of pegylated single wall carbon nanotubes in pregnant mice," *Particle and Fibre Toxicology*, vol. 10, no. 1, pp. 1–13, 2013.

[19] S. S. Martin, M. J. Blaha, M. B. Elshazly et al., "Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications," *Journal of the American College of Cardiology*, vol. 62, no. 8, pp. 732–739, 2013.

[20] G. Luca, J. Vienne, A. Vaucher, S. Jimenez, and M. Tafti, "Central and peripheral metabolic changes induced by gamma-hydroxybutyrate," *Sleep*, vol. 38, no. 2, pp. 305–313, 2015.

[21] A. Gastaldelli, K. Cusi, M. Pettiti et al., "Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects," *Gastroenterology*, vol. 133, no. 2, pp. 496–506, 2007.

[22] R. Zimmermann, J. G. Strauss, G. Haemmerle et al., "Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase," *Science*, vol. 306, no. 5700, pp. 1383–1386, 2004.

[23] E. E. Kershaw, J. K. Hamm, L. A. W. Verhagen, O. Peroni, M. Katic, and J. S. Flier, "Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin," *Diabetes*, vol. 55, no. 1, pp. 148–157, 2006.

[24] X. Chen, N. Iqbal, and G. Boden, "The effects of free fatty acids on gluconeogenesis and glycolysis in normal subjects," *The Journal of Clinical Investigation*, vol. 103, no. 3, pp. 365–372, 1999.

[25] L. Laffel, "Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes," *Diabetes/Metabolism Research and Reviews*, vol. 15, no. 6, pp. 412–426, 1999.

[26] L. Rui, "Energy metabolism in the liver," *Comprehensive Physiology*, vol. 4, no. 1, pp. 177–197, 2014.

[27] G. Bedogni, L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini, and S. Bellantini, "Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study," *Hepatology*, vol. 42, no. 1, pp. 44–52, 2005.

[28] M. Lemoine, I. Serfaty, and J. Capeau, "From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients," *Current Opinion in Infectious Diseases*, vol. 25, no. 1, pp. 10–16, 2012.

[29] I. J. Goldberg, R. H. Eckel, and N. A. Abumrad, "Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways," *Journal of Lipid Research*, vol. 50, Supplement, pp. S86–S90, 2009.

[30] J. Kernier and C. Hoppel, "Fatty acid import into mitochondria," *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*, vol. 1486, no. 1, pp. 1–17, 2000.

[31] Y. Poirier, V. D. Antonenkov, T. Glumoff, and J. K. Hiltunen, " Peroxisomal β-oxidation—a metabolic pathway with multiple functions," *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, vol. 1763, pp. 1413–1426, 2006.

[32] A. W. Ferrante, "Obesity-induced inflammation: a metabolic dialogue in the language of inflammation," *Journal of Internal Medicine*, vol. 262, no. 4, pp. 408–414, 2007.

[33] M. W. Schwartz, S. C. Woods, D. Porte, R. J. Seeley, and D. G. Baskin, "Central nervous system control of food intake," *Nature*, vol. 404, no. 6778, pp. 661–671, 2000.

[34] W. Zhang, S. Ambati, M. A. Della-Fera, Y. H. Choi, C. A. Baile, and T. M. Andacht, "Leptin modulated changes in adipose tissue protein expression in OB/OF mice," *Obesity*, vol. 19, no. 2, pp. 255–261, 2011.

[35] J. Galgani and E. Ravussin, "Energy metabolism, fuel selection and body weight regulation," *International Journal of Obesity*, vol. 32 Suppl 7, Suppl 7, pp. S109–S119, 2008.

[36] A. C. Könner, T. Klöckener, and J. C. Brüning, "Control of energy homeostasis by insulin and leptin: targeting the arcuate nucleus and beyond," *Physiology & Behavior*, vol. 97, no. 5, pp. 632–638, 2009.

[37] L. M. Brown, D. J. Clegg, S. C. Benoit, and S. C. Woods, "Intraventricular insulin and leptin reduce food intake and body weight in C57BL6J mice," *Physiology & Behavior*, vol. 89, no. 5, pp. 687–691, 2006.

[38] F. Pacifi, D. Della Morte, B. Capuani et al., "Peroxisiredoxin 6, a multiatkioxidant enzyme evolved in the pathophysiolog-ogy of chronic noncommunicable diseases," *Antioxidants & Redox Signaling*, vol. 30, no. 3, pp. 399–414, 2018.

[39] S. Ma, X. Zhang, L. Zheng et al., "Peroxisiredoxin 6 is a crucial factor in the initial step of mitochondrial clearance and is upstream of the PINK1-Parkin pathway," *Antioxidants & Redox Signaling*, vol. 24, no. 9, pp. 486–501, 2015.

[40] T. Eismann, N. Huber, T. Shin et al., "Peroxisiredoxin-6 protects against mitochondrial dysfunction and liver injury during ischemia-reperfusion in mice," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 296, no. 2, pp. G266–G274, 2008.

[41] G. M. Schmid, V. Converseit, N. Walter et al., "Effect of high-fat diet on the expression of proteins in muscle, adipose tissues, and liver of C57BL6 mice," *Proteomics*, vol. 4, no. 8, pp. 2270–2282, 2004.

[42] A. Nabeshima, S. Yamada, X. Guo et al., "Peroxisiredoxin 4 protects against nonalcoholic steatohepatitis and type 2 diabetes in a nongenetic mouse model," *Antioxidants & Redox Signaling*, vol. 19, no. 17, pp. 1983–1998, 2013.

[43] J. R. Roede, B. J. Stewart, and D. R. Petersen, "Decreased expression of peroxisiredoxin 6 in a mouse model of ethanol consumption," *Free Radical Biology & Medicine*, vol. 45, no. 11, pp. 1551–1558, 2008.

[44] D. Y. Koonen, R. L. Jacobs, M. Febbraio et al., "Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity," *Diabetes*, vol. 56, no. 12, pp. 2863–2871, 2007.

[45] J. He, J. H. Lee, M. Febbraio, and W. Xie, "The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease," *Experimental Biology and Medicine*, vol. 236, no. 10, pp. 1116–1121, 2011.

[46] V. V. Kunjathoor, M. Febbraio, E. A. Podrez et al., "Scaven-ger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages," *The Journal of Biological Chemistry*, vol. 277, no. 51, pp. 49982–49988, 2002.

[47] S. O. Rahaman, D. J. Lennon, M. Febbraio, E. A. Podrez, S. L. Hazen, and R. L. L. Silverstein, "A CD36-dependent signaling cascade is necessary for macrophage foam cell formation," *Cell Metabolism*, vol. 4, no. 3, pp. 211–221, 2006.

[48] B. M. De Taeye, T. Novitskaya, O. P. McGuinness et al., "Macrophage TNF-α contributes to insulin resistance and hepatic steatosis in diet-induced obesity," *American Journal of Physiology - Gastrointestinal and Liver Physiology*, vol. 322, no. 5, pp. G971–G981, 2007.
[49] H. Shi, H. J. Yu, H. Y. Wang et al., "Topical administration of peroxiredoxin-6 on the cornea suppresses inflammation and neovascularization induced by ultraviolet radiation," Investigative Ophthalmology and Visual Science, vol. 53, no. 13, pp. 8016–8028, 2012.

[50] F. M. M. Paula, S. M. Ferreira, A. C. Boschero, and K. L. A. Souza, "Modulation of the peroxiredoxin system by cytokines in insulin-producing RINm5F cells: down-regulation of PRDX6 increases susceptibility of beta cells to oxidative stress," Molecular and Cellular Endocrinology, vol. 374, no. 1-2, pp. 56–64, 2013.

[51] C. P. Day and O. F. W. James, "Steatohepatitis: a tale of two "hits"?" Gastroenterology, vol. 114, no. 4, pp. 842–845, 1998.

[52] Z. Chen, R. Yu, Y. Xiong, F. Du, and S. Zhu, "A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease," Lipids in Health and Disease, vol. 16, no. 1, pp. 1–9, 2017.

[53] J. D. McGarry, "Banting Lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes," Diabetes, vol. 51, no. 1, pp. 7–18, 2002.

[54] D. Greco, A. Kotronen, J. Westerbacka et al., "Gene expression in human NAFLD," American Journal of Physiology Gastrointestinal and Liver Physiology, vol. 294, no. 5, pp. G1281–G1287, 2008.

[55] Q. Tu, Y. Xiong, L. Fan et al., "Peroxiredoxin 6 attenuates ischemia- and hypoxia-induced liver damage of brain-dead donors," Molecular Medicine Reports, vol. 13, no. 1, pp. 753–761, 2016.

[56] D. H. Lee, Y. Y. Jung, M. H. Park et al., "Peroxiredoxin 6 confers protection against non-alcoholic fatty liver disease through maintaining mitochondrial function," Antioxidants & Redox Signaling, vol. 31, no. 5, pp. 387–402, 2019.

[57] R. J. Nelson, "The use of genetic "knockout" mice in behavioral endocrinology research," Hormones and Behavior, vol. 31, no. 3, pp. 188–196, 1997.